Plasma kallistatin levels in patients with severe community-acquired pneumonia

Table 1 Comparisons between survivors and nonsurvivors of severe community-acquired pneumonia

Variables	Survivors (n= 41)	Nonsurvivors (n= 13)	P value
Age, year	76 (21-93)	77 (33-96)	0.142
Gender, male, n (%)	27 (66)	7 (54)	0.652
Comorbidities, n (%)
Diabetes	8 (20)	2 (15)	1.000
Chronic kidney disease	4 (10)	1 (8)	1.000
Chronic respiratory disease	7 (17)	2 (15)	1.000
Liver cirrhosis	2 (5)	1 (8)	1.000
Malignancy	5 (12)	1 (8)	1.000
ARDS, n (%)	7 (17)	7 (54)	0.025^a
Invasive mechanical ventilation, n (%)	33 (80)	13 (100)	0.176
Septic shock at ICU admission, n (%)	20 (49)	11 (85)	0.051^b
Positive blood cultures, n (%)	7 (17)	4 (31)	0.285
APACHE II score, points	18 (6-36)	25 (14-40)	0.027^a
SOFA score, points
Day 1	6 (0-15)	14 (3-18)	0.018^a
Day 4	5 (0-18)	8.5 (2-17)	0.045^a
CURB-65 score, points
Day 1	3 (2-5)	4 (3-5)	0.002^a
Day 4	3 (0-5)	4 (1-5)	0.021^a
ICU stay, days	9 (3-64)	13 (2-47)	0.277
Hospital stay, days	20 (9-64)	18 (2-52)	0.302
Mechanical ventilation, days	8 (0-67)	13 (2-48)	0.247

Data are presented as median (range), unless stated otherwise. APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, acute respiratory distress syndrome; CURB-65, confusion of new onset (defined as an abbreviated mental test score of 8 or less), urea >7 mM (19 mg/dl), respiratory rate of 30 breaths per minute or greater, blood pressure <90 mm Hg systolic or diastolic blood pressure 60 mm Hg or less, and age 65 years or older; ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment. ^aStatistically significant. ^bNearly statistically significant.

ISSN: 1364-8535